Loading...
XSHE300199
Market cap1.26bUSD
Jan 14, Last price  
11.82CNY
1D
4.60%
1Q
7.85%
Jan 2017
-34.26%
IPO
223.84%
Name

Hybio Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300199 chart
P/E
—
P/S
21.47
EPS
—
Div Yield, %
1.27%
Shrs. gr., 5y
-0.77%
Rev. gr., 5y
-19.35%
Revenues
431m
-38.75%
56,201,63277,359,19092,711,443121,928,511165,681,027225,995,986301,404,772419,428,160768,263,801855,047,9091,246,233,5031,264,444,507614,191,475721,723,507735,971,144704,321,731431,384,112
Net income
-514m
15,232,19919,858,82135,365,91152,847,19980,474,38589,799,022129,930,721171,561,684305,342,048291,924,689329,721,38000030,807,7910-513,876,149
CFO
-4m
L
045,745,34626,108,70954,693,33972,475,37787,186,870153,475,921153,425,926138,840,479296,411,774213,741,34846,998,356104,636,57947,990,836156,827,37815,807,431-3,536,580
Dividend
Apr 19, 20180.2 CNY/sh
Earnings
May 16, 2025

Profile

Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.
URL
https://www.hybio.com.cn/
IPO date
Apr 07, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
431,384
-38.75%
704,322
-4.30%
Cost of revenue
692,158
717,321
Unusual Expense (Income)
NOPBT
(260,774)
(12,999)
NOPBT Margin
Operating Taxes
4,339
Tax Rate
NOPAT
(265,114)
(12,999)
Net income
(513,876)
 
Dividends
(117,898)
Dividend yield
0.98%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
617,413
774,914
Long-term debt
938,761
1,025,832
Deferred revenue
101,189
118,620
Other long-term liabilities
25,788
20,560
Net debt
1,212,168
1,533,913
Cash flow
Cash from operating activities
(3,537)
15,807
CAPEX
(81,763)
Cash from investing activities
147,711
51,716
Cash from financing activities
95,846
FCF
231,872
72,254
Balance
Cash
344,007
266,832
Long term investments
3
Excess cash
322,437
231,616
Stockholders' equity
(680,272)
1,154,262
Invested Capital
3,146,427
2,981,186
ROIC
ROCE
EV
Common stock shares outstanding
885,993
883,241
Price
13.58
-22.75%
17.58
39.41%
Market cap
12,031,790
-22.51%
15,527,383
39.41%
EV
13,268,365
17,087,601
EBITDA
(105,858)
127,593
EV/EBITDA
133.92
Interest
125,767
103,249
Interest/NOPBT